Pirouette Medical
- Industry
- Pharmaceuticals
- Founded Year
- 2017
- Headquarters
- Portsmouth, New Hampshire, USA
- Employee Count
- 12
Key People
- Conor Cullinane - CEO and Co-founder
- Matthew Kane - Co-founder
- Elijah Kapas - Co-founder and Chief Technology Officer
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The founding team comprises experienced professionals with backgrounds in aerospace, medical devices, and FDA-regulated industries.
The founders, including Conor Cullinane, Matthew Kane, and Elijah Kapas, bring a wealth of experience from prestigious institutions like MIT and Clarkson University. Their combined backgrounds in engineering and healthcare innovation provide a solid foundation for developing and commercializing medical devices.
- Clinical Need
-
Aspect: Very Strong
Summary: Pirouette addresses a significant need for user-friendly, portable auto-injectors for emergency and routine care.
The current market lacks compact and intuitive auto-injectors, leading to challenges in patient compliance and timely administration. Pirouette's innovations aim to fill this gap by providing devices that are easy to use and carry, thereby improving patient outcomes.
- Competition
-
Aspect: Somewhat crowded
Summary: The auto-injector market has established players, but Pirouette's unique design offers differentiation.
Major pharmaceutical companies dominate the auto-injector space. However, Pirouette's emphasis on a disk-shaped, button-activated design addresses common user concerns, potentially capturing market share from traditional designs.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing a novel auto-injector involves engineering challenges, but the team has the expertise to address them.
Creating a compact, user-friendly auto-injector that meets regulatory standards involves complex engineering. The team's background in aerospace and medical devices equips them to navigate these challenges effectively.
- Patent
-
Aspect: Very Strong
Summary: Pirouette holds 18 issued patents, providing robust intellectual property protection.
The patents cover various aspects of the auto-injector design and functionality, preventing competitors from easily replicating the technology and ensuring a strong market position.
- Financing
-
Aspect: Well-funded
Summary: The company has raised over $14.6 million in funding, indicating strong investor confidence.
Investments from reputable firms like Y Combinator and Safar Partners provide the financial resources necessary for scaling operations and achieving regulatory milestones.
- Regulatory
-
Aspect: Pivotal Trial
Summary: Pirouette is progressing through design validation and preparing for FDA submissions.
The company is engaging in pre-NDA meetings with the FDA and focusing on producing registration batches, indicating a structured approach to meeting regulatory requirements.
Opportunity Rollup
- Odds of Success
- 3.85
- Peak Market Share
- 4.85
- Segment CAGR
- 2.4%
- Market Segment
- Drug Delivery Devices
- Market Sub Segment
- Auto-Injectors
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.73 |
| 3 | 1.70 |
| 4 | 3.39 |
| 5 | 4.85 |
Key Takeaway
Pirouette Medical's innovative auto-injector design addresses a significant market need, supported by a strong team and robust patent portfolio, positioning the company for potential success in the evolving drug delivery landscape.